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ABSTRACT 50 
Topic: To determine until what age children are at risk for pineal trilateral 51 
retinoblastoma (TRb), whether its onset is linked to the age at which intraocular 52 
retinoblastomas develop, and the lead time from a detectable pineal TRb to 53 
symptoms. 54 
Clinical relevance: About 45% of patients with retinoblastoma – those with a 55 
germline RB1 pathogenic variant – are at risk for pineal TRb. Early detection and 56 
treatment is essential for survival. Current evidence is unclear on the usefulness of 57 
screening for pineal TRb and, if useful, until what age screening should be continued. 58 
Methods: We conducted a study according to the MOOSE guideline for reporting 59 
meta-analyses of observational studies. We searched PubMed and Embase between 60 
January 1, 1966, and February 27, 2019, for published literature. We considered 61 
articles reporting patients with TRb with survival and follow-up data. Inclusion of 62 
articles was performed separately and independently by two authors, and two 63 
authors also independently extracted the relevant data. They resolved discrepancies 64 
by consensus.  65 
Results: One hundred thirty-eight patients with pineal TRb were included. Of 22 66 
asymptomatic patients, 21 (95%) were diagnosed before the age of 40 months 67 
(median 16, interquartile range 9–29). Age at diagnosis of pineal TRb in patients 68 
diagnosed with retinoblastoma at ≤6 months versus >6 months of age were 69 
comparable (P=0.44), suggesting independency between the ages at diagnosis of 70 
intraocular retinoblastoma and pineal TRb. The laterality of intraocular retinoblastoma 71 
and its treatment were unassociated with the age when the pineal TRb was 72 
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diagnosed. The lead time from an asymptomatic to a symptomatic pineal TRb was 73 
approximately 1 year. By performing a screening magnetic resonance imaging scan 74 
every 6 months after the diagnosis of heritable retinoblastoma (median age 6 75 
months) until the age of 36 months, at least 311 and 776 scans would be required to 76 
detect one asymptomatic pineal TRb and to save one life, respectively.  77 
Conclusion: Patients with retinoblastoma are at risk for pineal trilateral 78 
retinoblastoma for a shorter period than previously assumed and the age at 79 
diagnosis of pineal trilateral retinoblastoma is independent of the age at diagnosis of 80 




Trilateral retinoblastoma refers to retinoblastoma presenting with a midline 84 
intracranial neoplasm resembling an embryonal tumor of the central nervous system. 85 
Patients with trilateral retinoblastoma – of whom three quarters have pineal trilateral 86 
retinoblastoma (pineoblastoma) and one quarter a supra- or parasellar trilateral 87 
retinoblastoma – are carriers of a germline RB1 pathogenic variant who typically will 88 
also have bilateral intraocular retinoblastoma. Trilateral retinoblastoma is an 89 
important cause of death among patients with heritable retinoblastoma. 90 
The incidence of pineal trilateral retinoblastoma according to our recent systematic 91 
review and meta-analysis is 3.2% (95% confidence interval [CI] 1.4–5.6) of all 92 
patients with heritable retinoblastoma (bilateral and unilateral tumors with family 93 
history or a germline RB1 pathogenic variant) and 2.9% (95% CI 1.9–4.2) of patients 94 
with bilateral retinoblastoma.1 Because 45% of all retinoblastomas are heritable,2 and 95 
approximately 8000 new patients are expected globally each year,3 should all of them 96 
survive trilateral retinoblastoma is predicted to affect around 125 children annually, 97 
and 90 of them would develop a pineal trilateral retinoblastoma. 98 
Unlike non-pineal trilateral retinoblastomas, pineal trilateral retinoblastomas are often 99 
diagnosed after the intraocular tumor (metachronous).4 The often metachronous 100 
diagnosis of pineal trilateral retinoblastoma raises the question whether, and at which 101 
frequency, neuroradiologic screening should be adopted for a child with a germline 102 
RB1 pathogenic variant.  103 
In practice, most centers follow the recommendation to perform a brain magnetic 104 
resonance imaging (MRI) for children with retinoblastoma at diagnosis.4-8 Some 105 
centers, on the other hand, repeat the MRI for children up to 5 years of age,9 106 
although the benefit from this practice is unclear.10 107 
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Whether screening for pineal trilateral retinoblastoma is useful is unclear until this 108 
day. The objective of this article is to contribute to solving this problem by answering 109 
two previously unanswered questions:  110 
1. Until which age are patients with heritable retinoblastoma ‘at risk’ for pineal 111 
trilateral retinoblastoma? 112 
2. Does pineal trilateral retinoblastoma develop earlier if a patient is diagnosed 113 
with retinoblastoma at an early age (≤ 6 months)? 114 
METHODS 115 
Search strategy, study selection and data extraction 116 
We performed this study according to the EQUATOR (enhancing the quality and 117 
transparency of health research) reporting guidelines, including meta-analysis of 118 
observational studies in epidemiology a proposal for reporting (MOOSE).11 This study 119 
adhered to the declaration of Helsinki. The ethics committee (METc VUmc) approved 120 
this study with a waiver of informed consent. 121 
We updated our literature search for English, Dutch and German literature for 122 
patients with trilateral retinoblastoma as performed for the 2014 systematic review 123 
and meta-analysis by De Jong et al.4 with a new search (PubMed and Embase) 124 
performed on February 27, 2019 (Appendix A, performed by MCJ with 9 years of 125 
experience in conducting systematic reviews and meta-analyses). To ensure 126 
sensitivity the search strategy only included terms describing the target disease 127 
(Appendix A). Two authors (MCJ and ACM) independently reviewed all articles for 128 
inclusion and two authors (MCJ and WAK) independently extracted data from the 129 
included articles. We extracted all data as previously described4 to update our entire 130 
trilateral retinoblastoma database. If the trilateral retinoblastoma was diagnosed 131 
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within 3 months of diagnosis of intraocular tumor we considered the tumors 132 
synchronous. Patients were included if they were identifiable as unique and if at least 133 
the age at which the trilateral retinoblastoma was diagnosed was available. Overlap 134 
between patients was identified using all available data in included studies (such as 135 
age at diagnosis, gender and hospital where patient was treated); if uncertainty 136 
remained the most recently published case was excluded. Discrepancies were 137 
resolved by consensus.  138 
Authors of papers published ≥1995 were contacted via e-mail (on October 2017 and 139 
February 2019) for additional information relevant to the research questions (whether 140 
there was a screening program for trilateral retinoblastoma in place, whether it was 141 
detected during screening of after development of symptoms, and whether and when 142 
a previous negative scan was performed), however, none responded.  143 
Risk of bias and study quality 144 
Risk of bias and methodological quality of each article was assessed with a checklist 145 
proposed by Murad et al.12 Checklist items 5 and 6 were not included because they 146 
are only relevant to adverse drug events. Two authors (MCJ and RWJ) independently 147 
scored all included articles according to the checklist. Discrepancies were resolved 148 
by consensus. 149 
Overall level of evidence 150 
We graded the level of evidence of the two research questions stated in the 151 
introduction according to the GRADE system.13  152 
Statistical analysis 153 
We used IBM SPSS Statistics (version 22). The cumulative frequency of trilateral 154 
retinoblastoma by age at diagnosis and by the time from intraocular retinoblastoma 155 
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was plotted. The Mann-Whitney U test was used to compare subgroups. Spearman's 156 
ρ was used to calculate a correlation between two continuous variables. P-values 157 
<0.05 were considered statistically significant. All tests were two-sided. 158 
For the main analyses, data of patients diagnosed in 1995 or later were included (see 159 
prior publication14, 15). We consider that this period, beginning with the introduction of 160 
chemotherapy to the routine management of retinoblastoma, most accurately 161 
corresponds to management today in terms of diagnostic modalities and treatment 162 
for both intraocular retinoblastoma and trilateral retinoblastoma. We used data from 163 
patients diagnosed before 1995 to check the robustness of our analyses in case 164 
sample sizes were small.  165 
RESULTS 166 
Included studies and patients 167 
Our updated search resulted in 185 PubMed and 336 Embase hits (Appendix B). 168 
After exclusion of 52 duplicates, we reviewed 469 titles and abstracts for eligibility 169 
and excluded 451 articles. Eighteen articles were eligible and we reviewed their full 170 
text. One article10 included only previously published patients. Six articles16-21 did not 171 
provide the age at diagnosis of trilateral retinoblastoma, two22, 23 reported on patients 172 
with a trilateral retinoblastoma but without an intraocular tumor, and three24-26 did not 173 
report on patients with trilateral retinoblastoma at all and were excluded. The six 174 
remaining articles27-32 provided fifteen new patients. Together with 174 patients from 175 
our earlier systematic review,4 we compiled data from 189 patients with trilateral 176 
retinoblastoma (Appendix C).  177 
Of all patients, 138 (73%) had a pineal trilateral retinoblastoma, 42 (22%) had a 178 
supra- or parasellar or ventricular trilateral retinoblastoma, and 3 (2%) had both a 179 
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pineal and a non-pineal trilateral retinoblastoma;5, 33 in the remaining patients (3%), 180 
the location of the trilateral retinoblastoma was unspecified. Of the 183 patients with 181 
a trilateral retinoblastoma in a known location, 73 (40%) were diagnosed in 1995 or 182 
later of whom 50 (68%) had a pineal trilateral retinoblastoma, 21 (29%) had a non-183 
pineal trilateral retinoblastoma, and 2 (3%) had both tumors; 37 (51%) of them were 184 
synchronous, 28 (38%) were metachronous, one was diagnosed before the 185 
intraocular tumor, and in 7 (11%) patients the sequence was unspecified. Restricting 186 
to pineal trilateral retinoblastoma, of the 50 patients diagnosed in 1995 or later, 18 187 
(36%) had synchronous tumors, 26 (52%) metachronous tumors, and in 6 (12%) 188 
patients this was unspecified. 189 
 190 
Risk of bias and study quality 191 
Of the 96 included articles, 74 (71%) did not fulfill the first criterion in the quality 192 
checklist (Appendix D), indicating that they likely reported patients that were 193 
interesting and did not necessarily present the entire experience the authors had with 194 
trilateral retinoblastoma. In seventeen (18%) studies one or more false positive 195 
diagnosis could not be entirely ruled out (e.g., patient 151 in appendix C had no 196 
follow-up and a small presumed cystic pineal trilateral retinoblastoma of 11 mm).  197 
 198 
Cumulative frequency of having pineal trilateral retinoblastoma diagnosed 199 
We stratified the cumulative frequency of pineal trilateral retinoblastoma according to 200 
the presence or absence of symptoms (Figure 1). The distribution of the ages at 201 
which pineal trilateral retinoblastoma was diagnosed differed significantly between 202 
the groups (P=0.0026, Mann-Whitney U test). The two cumulative frequency curves 203 
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were separated by approximately 1 year, which we interpret as the lead time from a 204 
pineal trilateral retinoblastoma detectable on MRI to the onset of symptoms.  205 
The median largest diameter of an asymptomatic versus a symptomatic pineal 206 
trilateral retinoblastoma was 13 mm (interquartile range [IQR] 11–16 mm) versus 29 207 
mm (IQR 22–36 mm; P=0.0004, Mann-Whitney U test).  208 
No correlation between the age at diagnosis of a pineal trilateral retinoblastoma and 209 
its diameter was observed in either among (including patients diagnosed before 1995 210 
to ensure a larger sample size, because tumor size often was unreported; Appendix 211 
E) 31 asymptomatic patients (ρ=-0.11; P=0.56; Spearman) or among 44 symptomatic 212 
ones (ρ=-0.15; P=0.33).  213 
Of 22 patients with an asymptomatic pineal trilateral retinoblastoma, all but one 214 
(95%) were diagnosed before 40 months of age (median 16, IQR 9–29; one outlier at 215 
56 months; Figure 1). Also, the slope of the cumulative frequency curve for both 216 
asymptomatic and symptomatic pineal trilateral retinoblastoma is nearly consistent, 217 
suggesting that the likelihood of being diagnosed with pineal trilateral retinoblastoma 218 
within the period at risk is approximately constant and unassociated with age. 219 
We found no difference in the age at which an asymptomatic pineal trilateral 220 
retinoblastoma was diagnosed in 11 patients before 1995 (median 14 months, IQR 221 
10–36) compared to 22 patients in 1995 and later (median 16 months, IQR 9–29; 222 
P=0.49, Mann-Whitney U test). The same was true of a symptomatic pineal trilateral 223 
retinoblastoma (median 34 months; IQR 24–39 vs. 36 months; IQR 22–45, 224 
respectively; P=0.81). The age at which a pineal trilateral retinoblastoma was 225 
diagnosed was also similar for patients who had their intraocular retinoblastoma 226 
diagnosed at the age of 6 months or earlier vs. those with a later diagnosis whether 227 
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analyzing all, asymptomatic, or symptomatic patients (P= 0.44, 0.94 and 0.57, 228 
respectively; Figure 2 and Appendix F). 229 
The cumulative frequency curve of the interval from diagnosis of an intraocular 230 
retinoblastoma to pineal trilateral retinoblastoma showed that patients diagnosed with 231 
intraocular retinoblastoma after 6 months of age develop pineal trilateral 232 
retinoblastoma after a shorter interval than those diagnosed at a younger age 233 
whether considering all, asymptomatic or symptomatic patients (Figure 3, P= 0.0004, 234 
0.011 and 0.045, respectively, Mann-Whitney U test). Including in the analysis 235 
patients diagnosed with pineal trilateral retinoblastoma before 1995, or restricting 236 
analysis to that period, produced similar results (Appendix G).  237 
When comparing the age at diagnosis of an asymptomatic pineal trilateral 238 
retinoblastoma versus an asymptomatic non-pineal trilateral retinoblastoma the 239 
cumulative frequency curves overlapped (Figure 4, P=0.38, Mann-Whitney U test).  240 
Patients with bilateral and unilateral retinoblastoma were diagnosed with pineal 241 
trilateral retinoblastoma at comparable ages (including patients diagnosed before 242 
1995) whether the intracranial tumor was asymptomatic (P=0.52, Mann-Whitney U 243 
test) or symptomatic (P=0.83, Appendix H). 244 
Prior treatment and metachronous pineal trilateral retinoblastoma   245 
To evaluate the potential effect of previous systemic chemotherapy on the interval 246 
from intraocular retinoblastoma to pineal trilateral retinoblastoma we compared 247 
patients who were diagnosed with metachronous tumors either before or from 1995 248 
onward restricting analyses to the latter period yielded a small sample size for no 249 
chemotherapy because chemotherapy was prevalent from 1995 onward. Patients 250 
who did not receive prior chemotherapy were diagnosed with pineal trilateral 251 
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retinoblastoma similarly to those who did receive chemotherapy (Appendix I, P=0.38, 252 
Mann-Whitney U test). 253 
Patients who did not receive prior external beam radiotherapy were diagnosed with 254 
pineal trilateral retinoblastoma similarly to those who did receive such radiotherapy 255 
(Appendix J, P=0.65, Mann-Whitney U test). 256 
Potential implications for screening 257 
A lead time of approximately 1 year (with growth in that time from a median diameter 258 
of 13 mm to 29 mm; and a decrease in 5-year survival from 50% to 21% when 259 
diameter exceeds 15 mm4) suggests that a screening program should include scans 260 
more frequently than once a year. Assuming that patients with known heritable 261 
retinoblastoma are screened every 6 months until the age of 36 months regardless of 262 
age at diagnosis of the intraocular tumor, this results in a screening MRI scan at the 263 
ages of 1, 1.5, 2, 2.5 and 3 years. An additional scan at 6 months of age is needed 264 
for familial retinoblastoma screened from birth and for other neonatal or early 265 
diagnoses.34 These scans would also capture any rare metachronous non-pineal 266 
trilateral retinoblastomas. 267 
Given that 50% of pineal trilateral retinoblastomas are diagnosed at the baseline MR 268 
scan,1  and that 5% of pineal trilateral retinoblastoma would be diagnosed after the 269 
age of 36 months (assuming that the patient diagnosed with an asymptomatic 270 
pineoblastoma at 38 months would have been diagnosed through MRI performed at 271 
36 months), we estimate a metachronous pineal trilateral retinoblastoma incidence of 272 
1.6% during the screening period. Assuming a sensitivity of 100% for MRI to detect 273 
an asymptomatic pineal trilateral retinoblastoma and no symptomatic ones emerging 274 
between scans, we would need to screen 1/0.016 = 62.5 patients with MRI to 275 
diagnose one asymptomatic metachronous pineal trilateral retinoblastoma. Assuming 276 
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an even distribution of diagnoses during the screening interval from 6 to 36 months 277 
(i.e. 0.2 positive scan every 6 months), we would require 62.5 scans in the first round, 278 
and 62.3, 62.1, 61.9, and 61.7 subsequent rounds, amounting to 310.5 MRI scans in 279 
total. With a survival rate of approximately 50% for asymptomatic and 10% for 280 
symptomatic patients,4 the screening program would be able to save one life for 281 
every 310.5/0.5*5/4=776.25 MRI scans. These numbers will increase with a lower 282 
sensitivity of MRI and any symptomatic interval pineal trilateral retinoblastoma. Also, 283 
the possibility of overdiagnosis (false positive) would risk unnecessary treatment with 284 
its associated morbidity and mortality. High dose chemotherapy with stem cell rescue 285 
caries a risk of toxic adverse effects, including death reported in 1 of 41 cases.35-37 286 
 287 
Overall level of evidence 288 
Appendix K outlines the GRADE level of evidence. The overall level of evidence is of 289 
low quality, i.e., this research provides some indication of the likely effect. However, 290 
the likelihood that it will be substantially different (a large enough difference that it 291 
might have an effect on a decision) is high.  292 
 293 
DISCUSSION 294 
We found that the age at which intraocular retinoblastoma and pineal trilateral 295 
retinoblastoma are diagnosed are unassociated with each other. This suggests 296 
independent development of intraocular retinoblastoma and pineal trilateral 297 
retinoblastoma, a conclusion strengthened by the fact that the age at diagnosis of 298 
pineal trilateral retinoblastoma also was unassociated with the laterality of the 299 
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intraocular retinoblastoma that may reflect varying penetrance and expressivity of the 300 
germline RB1 pathogenic variant during retinal development. 301 
We found no association between prior chemotherapy or radiotherapy for intraocular 302 
retinoblastoma and the interval to detection of pineal trilateral retinoblastoma. 303 
Consequently, prior treatment probably can be ignored when considering a screening 304 
strategy to detect metachronous trilateral retinoblastoma.  305 
Previously4, 38 it was found that non-pineal trilateral retinoblastoma is diagnosed 306 
earlier than pineal trilateral retinoblastoma. This might in part be explained by a 307 
longer lead time bias in the diagnosis of symptomatic pineal trilateral retinoblastoma, 308 
however, not pineal tumors are less frequently detectable at baseline MRI than non-309 
pineal trilateral retinoblastomas. 310 
The retinoblastoma community currently agrees that a baseline brain MRI is standard 311 
of care to detect a synchronous trilateral retinoblastoma when intraocular 312 
retinoblastoma is diagnosed. Most question the benefit of performing additional 313 
imaging given the rarity of metachronous trilateral retinoblastoma. Our results do 314 
suggest that, should screening be opted for, it should be independent of age at which 315 
intraocular retinoblastoma is diagnosed. They also suggest that a screening program 316 
might only be required until the age of 36-40 months and that no specific age bracket 317 
exists that would require a variable screening approach (e.g., more or less frequent 318 
screening). With an estimated incidence of metachronous pineal trilateral 319 
retinoblastoma of under 2% in patients with heritable retinoblastoma, any screening 320 
program would require hundreds of MRI scans to detect one patient with an 321 
asymptomatic pineal trilateral retinoblastoma, and thus should undergo a thorough 322 




As noted in the previously published meta-analysis,4 our study is similarly limited by 326 
the heterogeneity of included patients. The problem of potential publication bias is 327 
illustrated by the checklist that showed that up to 71% of studies presented case 328 
reports or small case series, suggesting that the cases may not represent the entire 329 
experience of the center. Furthermore, in 18% of studies the possibility cannot be 330 
excluded that at least one of the patients in a particular series was not a false positive 331 
diagnosis, either because of deficient follow-up or because normal pineal glands may 332 
sometimes be difficult to differentiate from a small pineal trilateral retinoblastoma.39, 40 333 
However, the age at diagnosis of pineal trilateral retinoblastoma did not significantly 334 
differ in the group of patients with versus without confirmation. 335 
Ideally, our research question and protocol would have been solved and published 336 
earlier. However, the research question emerged from a recent unpredicted 337 
diagnosis of a metachronous pineal trilateral retinoblastoma by the co-authors from 338 
Toronto, Canada, which led to contact with the authors of the previous meta-analysis 339 
on survival after trilateral retinoblastoma.4 As a result, the prior meta-analysis 340 
protocol was adapted to provide the required answers. 341 
 342 
CONCLUSIONS 343 
Age at diagnosis of heritable intraocular retinoblastoma and pineal trilateral 344 
retinoblastoma likely are independent. Age at diagnosis of an asymptomatic non-345 
pineal trilateral retinoblastoma and an asymptomatic pineal trilateral retinoblastoma 346 
are similar, and unassociated with the age at diagnosis and laterality of the 347 
intraocular retinoblastoma. The lead time from a detectable pineoblastoma on MRI to 348 
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development of symptoms is approximately 1 year. Prior systemic chemotherapy or 349 
radiotherapy for intraocular retinoblastoma is unassociated with the age at diagnosis 350 
of pineal trilateral retinoblastoma. Ninety-five percent of patients with an 351 
asymptomatic pineal trilateral retinoblastoma are diagnosed before the age of 40 352 
months, which can be considered the period at risk of developing a pineal trilateral 353 
retinoblastoma. During this period, the risk of having a pineal trilateral retinoblastoma 354 
diagnosed is approximately constant over time. The GRADE level of evidence for 355 
these results remains low.  356 
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FIGURE LEGENDS 452 
 453 
Figure 1. Cumulative frequency plot of age at diagnosis of a pineal trilateral 454 
retinoblastoma in asymptomatic versus symptomatic disease. 455 
 456 
Figure 2. Scatterplot of age at diagnosis of intraocular retinoblastoma versus the age 457 
at pineal trilateral retinoblastoma diagnosis. Note the lack of patients diagnosed with 458 
pineal trilateral retinoblastoma before retinoblastoma (region in the lower right of the 459 
graph), which can be explained by our inclusion criteria: studies reporting on a ‘pineal 460 
trilateral retinoblastoma’ without intraocular retinoblastoma were excluded. Perhaps 461 
(some of) those patients did not survive long enough to develop intraocular 462 
retinoblastoma.  463 
 464 
Figure 3. Cumulative frequency plots of the interval between diagnosis of intraocular 465 
retinoblastoma and pineal trilateral retinoblastoma in patients diagnosed with 466 
intraocular retinoblastoma at ≤ 6 months of age and > 6 months of age (a) for all 467 
patients, (b) for asymptomatic patients, and (c) for symptomatic patients 468 
 469 
Figure 4. Cumulative frequency plot of age at diagnosis of trilateral retinoblastoma for 470 
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Patients with retinoblastoma are at risk for pineal trilateral retinoblastoma for a 
shorter time period than previously assumed and the age at diagnosis of pineal 
trilateral retinoblastoma seems to be independent of the age at diagnosis of 
retinoblastoma. 
